GlassScriptPhysician profile
Elizabeth Mazzone
NPI 1629456017
$4,910.49
in general payments reported to CMS, 2019-2025
26 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $131 · 2021: $37.72 · 2022: $38.43 · 2023: $343 · 2024: $3,887 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,073 · Education: $1,500 · Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,073.25 |
| Education | $1,500.00 |
| Food and Beverage | $978.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,639.45 | 2024 | |
| Hologic Sales and Service, LLC | $202.34 | 2019-2024 | Novasure, Acessa Provu System, Myosure Tissue Removal Device |
| Sumitomo Pharma America, INC. | $140.11 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $129.08 | 2019-2025 | |
| Exeltis, USA INC. | $94.56 | 2022-2025 | Slynd |
| Biogen, INC. | $92.90 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $83.61 | 2023-2025 | Veozah |
| Abbvie INC. | $83.55 | 2020-2023 | |
| Mayne Pharma Commercial LLC | $78.03 | 2023-2025 | |
| Coopersurgical, INC. | $45.99 | 2023 | Paragard T 380a |
| Aesculap, INC. | $40.42 | 2019 | |
| Pfizer INC. | $32.25 | 2023-2025 | |
| Roche Diagnostics Corporation | $29.59 | 2019 | |
| Meditrina | $29.54 | 2023-2024 | |
| Shield Therapeutics INC | $24.39 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $21.71 | 2024-2025 | Nexplanon |
| Kerecis Limited | $16.73 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Millicent US INC | $16.70 | 2025 | Femlyv |
| Lupin INC. | $16.56 | 2020 | |
| Covidien LP | $13.94 | 2020 | |
| Daiichi Sankyo INC. | $13.91 | 2019 | |
| Minerva Surgical, INC | $13.89 | 2019 | |
| Sanara Medtech INC. | $13.75 | 2022 | |
| Duchesnay USA Incorporated | $13.05 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.38 | 2020 | |
| Therapeuticsmd, INC. | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Mazzone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.